{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:14:50Z","timestamp":1794932090848,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The vasodilatory and neuroprotective properties of felodipine were characterized in normal and ischemic rabbit eyes, an ocular hypertension (OHT) rat model, and cultured human neuron-like cells. Blood flow in the optic nerve head (ONH) was measured using laser speckle flowgraphy following intravitreally injected felodipine into normal and ischemic rabbit eyes receiving endothelin-1 injection. Felodipine concentrations in the retina-choroidal tissue were determined using mass spectrometry, and ocular safety was assessed using in-life examinations and histopathology in rabbits. The number of retinal ganglion cells (RGCs) was counted following intravitreal felodipine injection in hypertonic saline-induced OHT rats. The in vitro neuroprotective effects of felodipine against vincristine-induced nuclear loss and neurite shortening were evaluated in differentiated SH-SY5Y neuron-like cells. Felodipine increased ONH blood flow in a dose-dependent manner in normal rabbit eyes. High felodipine dosage (780 nmol\/eye) improved blood circulation in endothelin-1-induced ischemic eyes. The ONH blood flow response to felodipine correlated with tissue concentration-time profiles. Even high dose of felodipine did not cause any ocular toxicity. Furthermore, felodipine protected SH-SY5Y cells against vincristine-induced damage and prevented OHT-induced RGC cell loss following its administration (40 nmol\/eye). Felodipine can act as a neuroprotectant against glaucomatous neuropathy via improved ONH microcirculation and direct neuroprotection of RGCs.<\/jats:p>","DOI":"10.1038\/s41598-025-09733-1","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T18:28:10Z","timestamp":1751567290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats"],"prefix":"10.1038","volume":"15","author":[{"given":"Takazumi","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Akaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Esaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Morofuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komei","family":"Okabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Fuwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vy","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najam A.","family":"Sharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Francesca","family":"Cordeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,3]]},"reference":[{"key":"9733_CR1","doi-asserted-by":"publisher","unstructured":"Weinreb, R. N. et al. Primary open-angle glaucoma. Nat. Rev. Dis. Primers 2 Preprint at (2016). https:\/\/doi.org\/10.1038\/nrdp.2016.67","DOI":"10.1038\/nrdp.2016.67"},{"key":"9733_CR2","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 121, 2081\u20132090 (2014).","journal-title":"Ophthalmology"},{"key":"9733_CR3","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/ph16060870","volume":"16","author":"NA Sharif","year":"2023","unstructured":"Sharif, N. A. Elevated intraocular pressure and glaucomatous optic neuropathy: genes to disease mechanisms, therapeutic drugs, and gene therapies. Pharmaceuticals 16, 870 (2023).","journal-title":"Pharmaceuticals"},{"key":"9733_CR4","doi-asserted-by":"publisher","first-page":"Preprintathttps","DOI":"10.1016\/j.mam.2023.101193","volume":"92","author":"JR Tribble","year":"2023","unstructured":"Tribble, J. R. et al. Neuroprotection in glaucoma: mechanisms beyond intraocular pressure Lowering. Mol. Asp Med. 92, Preprintathttpsdoiorg101016jmam2023101193 (2023).","journal-title":"Mol. Asp Med."},{"key":"9733_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1089\/jop.2017.0041","volume":"34","author":"S He","year":"2018","unstructured":"He, S., Stankowska, D. L., Ellis, D. Z., Krishnamoorthy, R. R. & Yorio, T. Targets of neuroprotection in glaucoma. J. Ocul Pharmacol. Ther. 34, 85\u2013106 (2018).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"9733_CR6","doi-asserted-by":"publisher","unstructured":"Sharif, N. A. Therapeutic drugs and devices for tackling ocular hypertension and glaucoma, and need for neuroprotection and cytoprotective therapies. Front. Pharmacol. 12, 729249 (2021). https:\/\/doi.org\/10.3389\/fphar.2021.729249","DOI":"10.3389\/fphar.2021.729249"},{"key":"9733_CR7","doi-asserted-by":"publisher","unstructured":"Mursch-Edlmayr, A. S., Bolz, M. & Strohmaier, C. Vascular aspects in glaucoma: From pathogenesis to therapeutic approaches. Int. J. Mol. Sci. 22 Preprint at (2021). https:\/\/doi.org\/10.3390\/ijms22094662","DOI":"10.3390\/ijms22094662"},{"key":"9733_CR8","doi-asserted-by":"publisher","unstructured":"Alarcon-Martinez, L. et al. Neurovascular dysfunction in glaucoma. Prog. Retin. Eye Res. 97 Preprint at (2023). https:\/\/doi.org\/10.1016\/j.preteyeres.2023.101217","DOI":"10.1016\/j.preteyeres.2023.101217"},{"key":"9733_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.preteyeres.2010.09.002","volume":"30","author":"M Araie","year":"2011","unstructured":"Araie, M. & Mayama, C. Use of calcium channel blockers for glaucoma. Prog Retin Eye Res. 30, 54\u201371 (2011). https:\/\/doi.org\/10.1016\/j.preteyeres.2010.09.002 Preprint at.","journal-title":"Prog Retin Eye Res."},{"key":"9733_CR10","first-page":"Preprintathttps","volume":"24","author":"X Wang","year":"2023","unstructured":"Wang, X. et al. The association between vascular abnormalities and glaucoma\u2014what comes first? Int. J. Mol. Sci. 24, Preprintathttpsdoiorg103390ijms241713211 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"9733_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41586-020-2589-x","volume":"585","author":"L Alarcon-Martinez","year":"2020","unstructured":"Alarcon-Martinez, L. et al. Interpericyte tunnelling nanotubes regulate neurovascular coupling. Nature 585, 91\u201395 (2020).","journal-title":"Nature"},{"key":"9733_CR12","doi-asserted-by":"crossref","unstructured":"Hara, H., Toriu, N., Shimazawa, M. & Hara, H. Clinical potential of lomerizine, a Ca 2\u2009+\u2009channel blocker as an anti-glaucoma drug: effects on ocular circulation and retinal neuronal damage. Cardiovasc Drug Rev 22, 199\u2013214 (2004).","DOI":"10.1111\/j.1527-3466.2004.tb00141.x"},{"key":"9733_CR13","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.ophtha.2008.05.015","volume":"115","author":"N Koseki","year":"2008","unstructured":"Koseki, N. et al. A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology 115, 2049\u20132057 (2008).","journal-title":"Ophthalmology"},{"key":"9733_CR14","doi-asserted-by":"publisher","unstructured":"Leung, G., Grant, A., Garas, A. N., Li, G. & Freeman, E. E. A systematic review and meta-analysis of systemic antihypertensive medications with intraocular pressure and glaucoma. Am. J. Ophthalmol. 255 7\u201317 Preprint at (2023). https:\/\/doi.org\/10.1016\/j.ajo.2023.03.014","DOI":"10.1016\/j.ajo.2023.03.014"},{"key":"9733_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.ophtha.2023.05.001","volume":"130","author":"JE Vergroesen","year":"2023","unstructured":"Vergroesen, J. E. et al. Association of systemic medication use with glaucoma and intraocular pressure: the European eye epidemiology consortium. Ophthalmology 130, 893\u2013906 (2023).","journal-title":"Ophthalmology"},{"key":"9733_CR16","doi-asserted-by":"crossref","unstructured":"Lee, J. S. et al. Effect of antihypertensive medications on the risk of open-angle glaucoma. Sci Rep 13, 16224 (2023).","DOI":"10.1038\/s41598-023-43420-3"},{"key":"9733_CR17","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2165\/00003495-198836040-00002","volume":"36","author":"E Saltiel","year":"1988","unstructured":"Saltiel, E., Ellrodt, A. G., Monk, J. P. & Langley, M. S. Felodipine. A review of its pharmacodynamic and Pharmacokinetic properties, and therapeutic use in hypertension. Drugs 36, 387\u2013428 (1988).","journal-title":"Drugs"},{"issue":"Suppl 1","key":"9733_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/00005344-198710001-00010","volume":"10","author":"JD Johnson","year":"1987","unstructured":"Johnson, J. D., Andrews, C. T., Khabbaza, E. J. & Mills, J. S. The interaction of felodipine with calcium-binding proteins. J. Cardiovasc. Pharmacol. 10 (Suppl 1), 53\u201359 (1987).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"9733_CR19","doi-asserted-by":"crossref","unstructured":"Siddiqi, F. H. et al. Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing. Nat Commun 10, 1817 (2019).","DOI":"10.1038\/s41467-019-10536-y"},{"key":"9733_CR20","doi-asserted-by":"crossref","unstructured":"Martinez, A. L. et al. Development of a novel in vitro assay to screen for neuroprotective drugs against iatrogenic neurite shortening. PLoS One 16, e0248139 (2021).","DOI":"10.1371\/journal.pone.0248139"},{"key":"9733_CR21","doi-asserted-by":"publisher","first-page":"123153","DOI":"10.1016\/j.ijpharm.2023.123153","volume":"642","author":"R Swain","year":"2023","unstructured":"Swain, R. et al. Ocular delivery of felodipine for the management of intraocular pressure and inflammation: effect of film plasticizer and in vitro in vivo evaluation. Int. J. Pharm. 642, 123153 (2023).","journal-title":"Int. J. Pharm."},{"key":"9733_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.exer.2006.03.007","volume":"83","author":"M Sasaoka","year":"2006","unstructured":"Sasaoka, M. et al. Intravitreal injection of endothelin-1 caused optic nerve damage following to ocular hypoperfusion in rabbits. Exp. Eye Res. 83, 629\u2013637 (2006).","journal-title":"Exp. Eye Res."},{"key":"9733_CR23","doi-asserted-by":"crossref","unstructured":"Kawakami, M. B. K. T. N. Vasodilator actions of felodipine, a new Ca2\u2009+\u2009entry blocker. Nihon Yakurigaku Zasshi 94, 251\u2013256 (1989).","DOI":"10.1254\/fpj.94.251"},{"key":"9733_CR24","doi-asserted-by":"crossref","unstructured":"Schocket, L. S., Grunwald, J. E. & Dupont, J. Effect of oral felodipine on ocular circulation. Int. Ophthalmol. 23, 79\u201384 (1999).","DOI":"10.1023\/A:1026585515630"},{"key":"9733_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1136\/bjo.2004.046755","volume":"89","author":"M Emre","year":"2005","unstructured":"Emre, M., Org\u00fcl, S., Haufschild, T., Shaw, S. G. & Flammer, J. Increased plasma endothelin-1 levels in patients with progressive open angle glaucoma. Br. J. Ophthalmol. 89, 60\u201363 (2005).","journal-title":"Br. J. Ophthalmol."},{"key":"9733_CR26","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41419-020-02990-0","volume":"11","author":"OJ Marola","year":"2020","unstructured":"Marola, O. J., Syc-Mazurek, S. B., Howell, G. R. & Libby, R. T. Endothelin 1-induced retinal ganglion cell death is largely mediated by JUN activation. Cell. Death Dis. 11, 811 (2020).","journal-title":"Cell. Death Dis."},{"key":"9733_CR27","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1167\/tvst.12.9.22","volume":"12","author":"S Sgambellone","year":"2023","unstructured":"Sgambellone, S. et al. NCX 470 exerts retinal cell protection and enhances ophthalmic artery blood flow after ischemia\/reperfusion injury of optic nerve head and retina. Transl Vis. Sci. Technol. 12, 22 (2023).","journal-title":"Transl Vis. Sci. Technol."},{"key":"9733_CR28","doi-asserted-by":"crossref","unstructured":"Taniguchi, T., Shimazawa, M., Sasaoka, M., Shimazaki, A. & Hara, H. Endothelin-1 impairs retrograde axonal transport and leads to axonal injury in rat optic nerve. Current Neurovascular Research 3, 81\u201388 (2006).","DOI":"10.2174\/156720206776875867"},{"key":"9733_CR29","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1089\/jop.2009.0100","volume":"26","author":"T Akaishi","year":"2010","unstructured":"Akaishi, T., Kurashima, H., Odani-Kawabata, N., Ishida, N. & Nakamura, M. Effects of repeated administrations of tafluprost, latanoprost, and Travoprost on optic nerve head blood flow in conscious normal rabbits. J. Ocul Pharmacol. Ther. 26, 181\u2013186 (2010).","journal-title":"J. Ocul Pharmacol. Ther."},{"key":"9733_CR30","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/exer.1996.0184","volume":"64","author":"JC Morrison","year":"1997","unstructured":"Morrison, J. C. et al. A rat model of chronic pressure-induced optic nerve damage. Exp. Eye Res. 64, 85\u201396 (1997).","journal-title":"Exp. Eye Res."},{"key":"9733_CR31","doi-asserted-by":"publisher","first-page":"6489","DOI":"10.1167\/iovs.16-20673","volume":"58","author":"S Husain","year":"2017","unstructured":"Husain, S. et al. PI3K\/Akt pathway: A role in \u03b4-opioid receptor-mediated RGC neuroprotection. Invest. Ophthalmol. Vis. Sci. 58, 6489\u20136499 (2017).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"9733_CR32","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1002\/cne.23521","volume":"522","author":"AR Rodriguez","year":"2014","unstructured":"Rodriguez, A. R., de Sevilla M\u00fcller, L. P. & Brecha, N. C. The RNA binding protein RBPMS is a selective marker of ganglion cells in the mammalian retina. J. Comp. Neurol. 522, 1411\u20131443 (2014).","journal-title":"J. Comp. Neurol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09733-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09733-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09733-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T18:28:11Z","timestamp":1751567291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-09733-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9733"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-09733-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,3]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23811"}}